Effects of leflunomide on immune responses and models of inflammation.
Bartlett
R R
RR
Pharmaceutical Research, Immunopharmacology Hoechst AG Werk, Wiesbaden, Germany.
Anagnostopulos
H
H
Zielinski
T
T
Mattar
T
T
Schleyerbach
R
R
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology* / Q000627:therapeutic use; D000917:Antibody Formation / Q000187:drug effects*; D001327:Autoimmune Diseases / Q000188:drug therapy; D016207:Cytokines / Q000378:metabolism; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D006084:Graft Rejection / Q000188:drug therapy; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects*; D007166:Immunosuppressive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D007249:Inflammation / Q000188:drug therapy*; D007555:Isoxazoles / Q000494:pharmacology* / Q000627:therapeutic use; D000077339:Leflunomide; D051379:Mice; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D051381:Rats
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016207:Cytokines; D007166:Immunosuppressive Agents; D007555:Isoxazoles; D011505:Protein-Tyrosine Kinases; D000077339:Leflunomide